8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Mar 3, 2026·SEC
Esperion Therapeutics, Inc.(ESPR)Earnings, Financials & Key Ratios
ESPR•NASDAQ
$3.15
$753M mkt cap·Price updated May 6, 2026
AboutEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Show more
- Revenue$403M+21.3%
- EBITDA$60M+10.9%
- Net Income-$23M+56.2%
- EPS (Diluted)-0.11+60.7%
- Gross Margin67.95%-14.4%
- EBITDA Margin14.98%-8.6%
- Operating Margin14.95%-8.7%
- Net Margin-5.63%+63.9%
- ROIC66.52%-49.9%
- Interest Coverage0.71-22.4%
ESPR Key Insights
Esperion Therapeutics, Inc. (ESPR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 12.1%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 11.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ESPR Price & Volume
Esperion Therapeutics, Inc. (ESPR) stock price & volume — 10-year historical chart
Loading chart...
ESPR Growth Metrics
Esperion Therapeutics, Inc. (ESPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years12.12%
3 Years74.8%
TTM21.31%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM56.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM30.32%
Return on Capital
10 Years-55.74%
5 Years-37.82%
3 Years-10.6%
Last Year45.89%
ESPR Recent Earnings
Esperion Therapeutics, Inc. (ESPR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Mar 10, 2026EPS
$0.22
Est $0.23
-4.3%
Revenue
$168M
Est $166M
+1.2%
Q4 2025
Nov 6, 2025EPS
$0.16
Est $0.09
-77.8%
Revenue
$87M
Est $165M
-47.1%
Q3 2025
Aug 5, 2025EPS
$0.02
Est $0.17
+88.2%
Revenue
$82M
Est $82M
-0.1%
Q2 2025
May 6, 2025EPS
$0.21
Est $0.18
-16.7%
Revenue
$65M
Est $61M
+6.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 10, 2026 | $0.22vs $0.23-4.3% | $168Mvs $166M+1.2% |
| Q4 2025 | Nov 6, 2025 | $0.16vs $0.09-77.8% | $87Mvs $165M-47.1% |
| Q3 2025 | Aug 5, 2025 | $0.02vs $0.17+88.2% | $82Mvs $82M-0.1% |
| Q2 2025 | May 6, 2025 | $0.21vs $0.18-16.7% | $65Mvs $61M+6.2% |
Based on last 12 quarters of dataView full earnings history →
ESPR Peer Comparison
Esperion Therapeutics, Inc. (ESPR) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 EWTX | 3.97B | 36.99 | -22.69 | -31.97% | 0.01 | |||
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 AMRN | 309.92M | 14.90 | -8.28 | -6.55% | -15.64% | -7.34% | 0.03 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 |
Compare ESPR vs Peers
Esperion Therapeutics, Inc. (ESPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ESPR Income Statement
Esperion Therapeutics, Inc. (ESPR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 184.47M | 148.36M | 227.55M | 78.45M | 75.47M | 116.33M | 332.31M | 403.13M |
| Revenue Growth % | - | - | -19.57% | 53.37% | -65.52% | -3.79% | 54.14% | 185.66% | 21.31% |
| Cost of Goods Sold | 258K | 265K | 0 | 2.39M | 14.22M | 26.97M | 43.27M | 68.6M | 129.22M |
| COGS % of Revenue | - | 0.14% | - | 1.05% | 18.12% | 35.73% | 37.19% | 20.64% | 32.05% |
| Gross Profit | -258K▲ 0% | 184.21M▲ 71498.8% | 148.36M▼ 19.5% | 225.16M▲ 51.8% | 64.23M▼ 71.5% | 48.51M▼ 24.5% | 73.07M▲ 50.6% | 263.71M▲ 260.9% | 273.91M▲ 3.9% |
| Gross Margin % | - | 99.86% | 100% | 98.95% | 81.88% | 64.27% | 62.81% | 79.36% | 67.95% |
| Gross Profit Growth % | -2.38% | 71498.84% | -19.46% | 51.76% | -71.47% | -24.48% | 50.63% | 260.92% | 3.87% |
| Operating Expenses | 168.98M | 204.59M | 241.47M | 346.55M | 290.96M | 228.01M | 228.63M | 209.31M | 213.64M |
| OpEx % of Revenue | - | 110.9% | 162.75% | 152.3% | 370.9% | 302.1% | 196.53% | 62.99% | 52.99% |
| Selling, General & Admin | 21.38M | 33.1M | 65.85M | 199.62M | 184.99M | 109.08M | 142.52M | 163.07M | 165.79M |
| SG&A % of Revenue | - | 17.94% | 44.39% | 87.72% | 235.81% | 144.53% | 122.51% | 49.07% | 41.12% |
| Research & Development | 147.6M | 171.49M | 175.61M | 146.94M | 105.97M | 118.93M | 86.11M | 46.24M | 47.85M |
| R&D % of Revenue | - | 92.96% | 118.37% | 64.57% | 135.09% | 157.57% | 74.02% | 13.91% | 11.87% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -168.98M▲ 0% | -204.59M▼ 21.1% | -93.1M▲ 54.5% | -121.4M▼ 30.4% | -226.73M▼ 86.8% | -179.5M▲ 20.8% | -155.56M▲ 13.3% | 54.4M▲ 135.0% | 60.27M▲ 10.8% |
| Operating Margin % | - | -110.9% | -62.75% | -53.35% | -289.02% | -237.83% | -133.72% | 16.37% | 14.95% |
| Operating Income Growth % | -121.91% | -21.07% | 54.49% | -30.39% | -86.77% | 20.83% | 13.34% | 134.97% | 10.79% |
| EBITDA | -168.72M | -204.32M | -92.78M | -120.85M | -226.12M | -179M | -155.4M | 54.47M | 60.38M |
| EBITDA Margin % | - | -110.76% | -62.54% | -53.11% | -288.24% | -237.17% | -133.58% | 16.39% | 14.98% |
| EBITDA Growth % | -122.3% | -21.1% | 54.59% | -30.25% | -87.11% | 20.84% | 13.19% | 135.05% | 10.86% |
| D&A (Non-Cash Add-back) | 258K | 265K | 319K | 547K | 612K | 500K | 164K | 63K | 105K |
| EBIT | -166.79M | -204.59M | -89.05M | -120.88M | -222.75M | -176.85M | -150.27M | 7.51M | 60.27M |
| Net Interest Income | 0 | 0 | -8.12M | -22.67M | -46.35M | -56.81M | -58.98M | -59.25M | -81.1M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.5M |
| Interest Expense | 198K | 100K | 8.12M | 22.67M | 46.35M | 56.81M | 58.98M | 59.25M | 84.6M |
| Other Income/Expense | 1.99M | 2.77M | -4.06M | -22.16M | -42.38M | -54.16M | -53.69M | -106.15M | 0 |
| Pretax Income | -166.99M▲ 0% | -201.81M▼ 20.9% | -97.17M▲ 51.9% | -143.55M▼ 47.7% | -269.11M▼ 87.5% | -233.66M▲ 13.2% | -209.25M▲ 10.4% | -51.74M▲ 75.3% | -20.84M▲ 59.7% |
| Pretax Margin % | - | -109.4% | -65.49% | -63.09% | -343.04% | -309.58% | -179.87% | -15.57% | -5.17% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.84M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -8.83% |
| Net Income | -166.99M▲ 0% | -201.81M▼ 20.9% | -97.17M▲ 51.9% | -143.55M▼ 47.7% | -269.11M▼ 87.5% | -233.66M▲ 13.2% | -209.25M▲ 10.4% | -51.74M▲ 75.3% | -22.68M▲ 56.2% |
| Net Margin % | - | -109.4% | -65.49% | -63.09% | -343.04% | -309.58% | -179.87% | -15.57% | -5.63% |
| Net Income Growth % | -122.72% | -20.85% | 51.85% | -47.74% | -87.47% | 13.17% | 10.45% | 75.27% | 56.17% |
| Net Income (Continuing) | -166.99M | -201.81M | -97.17M | -143.55M | -269.11M | -233.66M | -209.25M | -51.74M | -22.68M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.98▲ 0% | -7.54▼ 8.0% | -4.02▲ 46.7% | -6.05▼ 50.5% | -11.03▼ 82.3% | -4.33▲ 60.7% | -2.03▲ 53.1% | -0.28▲ 86.2% | -0.11▲ 60.7% |
| EPS Growth % | -109.61% | -8.02% | 46.68% | -50.5% | -82.31% | 60.74% | 53.12% | 86.21% | 60.71% |
| EPS (Basic) | -6.98 | -7.54 | -4.02 | -6.05 | -11.03 | -4.33 | -2.03 | -0.28 | -0.11 |
| Diluted Shares Outstanding | 23.93M | 26.75M | 27.09M | 27.47M | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
| Basic Shares Outstanding | 23.93M | 26.75M | 27.09M | 27.47M | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ESPR Balance Sheet
Esperion Therapeutics, Inc. (ESPR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 203.92M | 142.63M | 211.71M | 345.9M | 328.97M | 246.68M | 201.06M | 338M | 167.85M |
| Cash & Short-Term Investments | 34.47M | 36.97M | 200.78M | 304.96M | 259.33M | 166.86M | 82.25M | 144.76M | 167.85M |
| Cash Only | 34.47M | 36.97M | 166.13M | 304.96M | 208.89M | 124.78M | 82.25M | 144.76M | 167.85M |
| Short-Term Investments | 0 | 0 | 34.65M | 0 | 50.44M | 42.09M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 12.39M | 22.93M | 33.73M | 48.49M | 80.14M | 140.19M |
| Days Sales Outstanding | - | - | - | 19.87 | 106.71 | 163.11 | 152.15 | 88.02 | 126.93 |
| Inventory | 0 | 0 | 0 | 16.14M | 34.39M | 35.2M | 65.62M | 94.49M | 105.12M |
| Days Inventory Outstanding | - | - | - | 2.46K | 883.01 | 476.45 | 553.6 | 502.75 | 296.93 |
| Other Current Assets | 0 | 0 | 928K | 0 | 11.17M | 9.87M | 4.51M | 18.02M | -245.31M |
| Total Non-Current Assets | 73.91M | 819K | 2.73M | 7.36M | 52.62M | 1.26M | 4.73M | 5.82M | 298.03M |
| Property, Plant & Equipment | 435K | 520K | 2.68M | 7.31M | 2.56M | 1.2M | 4.67M | 5.77M | 3.26M |
| Fixed Asset Turnover | - | 354.76x | 55.42x | 31.15x | 30.62x | 62.90x | 24.88x | 57.62x | 123.66x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 56K | 56K | 56K | 56K | 0 | 0 | 56K | 56K | 56K |
| Long-Term Investments | 239.15M | 99.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -165.73M | -99.05M | 0 | 0 | 50M | 0 | 0 | 0 | -123.13M |
| Total Assets | 277.83M▲ 0% | 143.45M▼ 48.4% | 214.45M▲ 49.5% | 353.26M▲ 64.7% | 381.59M▲ 8.0% | 247.94M▼ 35.0% | 205.8M▼ 17.0% | 343.82M▲ 67.1% | 465.89M▲ 35.5% |
| Asset Turnover | - | 1.29x | 0.69x | 0.64x | 0.21x | 0.30x | 0.57x | 0.97x | 0.87x |
| Asset Growth % | 13.3% | -48.37% | 49.49% | 64.73% | 8.02% | -35.02% | -17% | 67.07% | 35.5% |
| Total Current Liabilities | 33.14M | 64.33M | 66.08M | 94.07M | 73.35M | 92.31M | 156.22M | 246.23M | 300.81M |
| Accounts Payable | 20.38M | 44.89M | 28.86M | 51.98M | 17.56M | 23.04M | 31.72M | 51.65M | 65.07M |
| Days Payables Outstanding | 28.83K | 61.83K | - | 7.93K | 450.8 | 311.85 | 267.57 | 274.81 | 183.79 |
| Short-Term Debt | 1.04M | 0 | 0 | 0 | 0 | 0 | 34.83M | 102.16M | 89.7M |
| Deferred Revenue (Current) | 38K | 0 | 2.15M | 1.66M | 5.68M | 3.51M | 25.4M | 8.52M | 0 |
| Other Current Liabilities | 10.99M | 1.88M | 7.82M | 15.16M | 8.81M | 9.05M | 49.24M | 12.74M | 146.04M |
| Current Ratio | 6.15x | 2.22x | 3.20x | 3.68x | 4.48x | 2.67x | 1.29x | 1.37x | 0.56x |
| Quick Ratio | 6.15x | 2.22x | 3.20x | 3.51x | 4.02x | 2.29x | 0.87x | 0.99x | 0.21x |
| Cash Conversion Cycle | - | - | - | -5.45K | 538.92 | 327.71 | 438.17 | 315.97 | 240.07 |
| Total Non-Current Liabilities | 0 | 0 | 128.42M | 355.32M | 505.18M | 479.41M | 504.57M | 486.31M | 467.04M |
| Long-Term Debt | 0 | 0 | 0 | 179.37M | 258.28M | 259.9M | 501.55M | 483.74M | 457.65M |
| Capital Lease Obligations | 0 | 0 | 1.11M | 3.45M | 524K | 665K | 3.02M | 2.57M | 653K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 417.85M |
| Other Non-Current Liabilities | 0 | 0 | 127.31M | 172.5M | 245.74M | 218.84M | 0 | 0 | 8.74M |
| Total Liabilities | 33.14M | 64.33M | 194.5M | 449.39M | 578.53M | 571.72M | 660.79M | 732.54M | 767.85M |
| Total Debt | 1.04M | 0 | 1.56M | 185.41M | 260.2M | 260.95M | 540.95M | 591.21M | 548M |
| Net Debt | -33.42M | -36.97M | -164.57M | -119.55M | 51.3M | 136.17M | 458.7M | 446.45M | 380.15M |
| Debt / Equity | 0.00x | - | 0.08x | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | 10.85x | 9.08x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 8.20x | 6.30x |
| Interest Coverage | -853.44x | -2045.85x | -11.47x | -5.35x | -4.89x | -3.16x | -2.64x | 0.92x | 0.71x |
| Total Equity | 244.69M▲ 0% | -598.1M▼ 344.4% | 19.95M▲ 103.3% | -96.13M▼ 581.9% | -196.94M▼ 104.9% | -323.78M▼ 64.4% | -454.99M▼ 40.5% | -388.72M▲ 14.6% | -301.96M▲ 22.3% |
| Equity Growth % | 7.04% | -344.43% | 103.34% | -581.87% | -104.86% | -64.4% | -40.53% | 14.57% | 22.32% |
| Book Value per Share | 10.22 | -22.36 | 0.74 | -3.50 | -6.81 | -4.88 | -4.41 | -2.08 | -1.45 |
| Total Shareholders' Equity | 244.69M | -598.1M | 19.95M | -96.13M | -196.94M | -323.78M | -454.99M | -388.72M | -301.96M |
| Common Stock | 26K | 27K | 27K | 26K | 61K | 75K | 118K | 196K | 245K |
| Retained Earnings | -396.29M | -598.1M | -695.27M | -838.82M | -1.11B | -1.34B | -1.55B | -1.6B | -1.62B |
| Treasury Stock | 0 | 0 | 0 | -55M | -55M | -55M | -55M | -55M | -55M |
| Accumulated OCI | -845K | -319K | 23K | 0 | -31K | -2K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ESPR Cash Flow Statement
Esperion Therapeutics, Inc. (ESPR) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -131.3M | -148.64M | -70.34M | -85.18M | -263.81M | -174.83M | -135.49M | -23.65M | -13.09M |
| Operating CF Margin % | - | -80.57% | -47.41% | -37.43% | -336.29% | -231.64% | -116.46% | -7.12% | -3.25% |
| Operating CF Growth % | -175.09% | -13.2% | 52.68% | -21.09% | -209.72% | 33.73% | 22.5% | 82.54% | 44.65% |
| Net Income | -166.99M | -201.81M | -97.17M | -143.55M | -269.11M | -233.66M | -209.25M | -51.74M | -22.68M |
| Depreciation & Amortization | 258K | 265K | 319K | 547K | 612K | 500K | 164K | 63K | 105K |
| Stock-Based Compensation | 18.61M | 23.97M | 25.88M | 28.39M | 24.31M | 15.21M | 11.96M | 11.99M | 9.87M |
| Deferred Taxes | 334K | 0 | 0 | -97K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 23K | -217K | 7.92M | 33.8M | 32.89M | 46.49M | 47.96M | 76.56M | 14.26M |
| Working Capital Changes | 16.47M | 29.16M | -7.3M | -4.26M | -52.51M | -3.37M | 13.68M | -60.53M | -14.64M |
| Change in Receivables | 0 | 0 | 0 | -10.74M | -10.55M | -10.79M | -14.77M | -31.65M | -60.05M |
| Change in Inventory | 0 | 0 | 0 | -16.14M | -18.26M | -807K | -30.42M | -28.87M | -10.63M |
| Change in Payables | 15.76M | 24.45M | -16.05M | 23.11M | -34.1M | 5.6M | 8.68M | 12.43M | 20.92M |
| Cash from Investing | -35.85M | 140.45M | 64.23M | 21.36M | -50.48M | 8.1M | 42.5M | -317K | 189K |
| Capital Expenditures | -19K | -151K | -953K | -13.37M | 0 | 0 | 0 | -317K | 189K |
| CapEx % of Revenue | - | 0.08% | 0.64% | 5.88% | - | - | - | 0.1% | 0.05% |
| Acquisitions | 0 | 0 | 0 | 12.5M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -35.83M | 140.6M | 0 | -12.5M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 163.46M | 10.69M | 136.19M | 201.72M | 268.22M | 32.61M | 50.46M | 86.48M | 36.18M |
| Debt Issued (Net) | -1.71M | -1.05M | 0 | 271.6M | -440K | 0 | 0 | 35.01M | -54.91M |
| Equity Issued (Net) | 1000K | 0 | 0 | -1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -55M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.17M | 11.74M | 136.19M | -14.87M | 49.98M | -58.24M | -6.42M | -39.72M | 244K |
| Net Change in Cash | -3.7M▲ 0% | 2.5M▲ 167.8% | 130.09M▲ 5093.0% | 137.9M▲ 6.0% | -46.07M▼ 133.4% | -134.12M▼ 191.1% | -42.53M▲ 68.3% | 62.51M▲ 247.0% | 23.09M▼ 63.1% |
| Free Cash Flow | -131.32M▲ 0% | -148.79M▼ 13.3% | -71.29M▲ 52.1% | -98.55M▼ 38.2% | -263.81M▼ 167.7% | -174.83M▲ 33.7% | -135.49M▲ 22.5% | -23.97M▲ 82.3% | -12.9M▲ 46.2% |
| FCF Margin % | - | -80.66% | -48.05% | -43.31% | -336.29% | -231.64% | -116.46% | -7.21% | -3.2% |
| FCF Growth % | -174.59% | -13.3% | 52.08% | -38.22% | -167.7% | 33.73% | 22.5% | 82.31% | 46.17% |
| FCF per Share | -5.49 | -5.56 | -2.63 | -3.59 | -9.13 | -2.63 | -1.31 | -0.13 | -0.06 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.74x | 0.72x | 0.59x | 0.98x | 0.75x | 0.65x | 0.46x | 0.58x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ESPR Key Ratios
Esperion Therapeutics, Inc. (ESPR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -29.07% | -70.56% | - | -487.04% | - | - | - | - | - | - |
| Return on Invested Capital (ROIC) | -28.04% | -62.67% | - | - | - | - | - | - | 132.83% | 66.52% |
| Gross Margin | - | - | 99.86% | 100% | 98.95% | 81.88% | 64.27% | 62.81% | 79.36% | 67.95% |
| Net Margin | - | - | -109.4% | -65.49% | -63.09% | -343.04% | -309.58% | -179.87% | -15.57% | -5.63% |
| Debt / Equity | 0.01x | 0.00x | - | 0.08x | - | - | - | - | - | - |
| Interest Coverage | -202.53x | -853.44x | -2045.85x | -11.47x | -5.35x | -4.89x | -3.16x | -2.64x | 0.92x | 0.71x |
| FCF Conversion | 0.64x | 0.79x | 0.74x | 0.72x | 0.59x | 0.98x | 0.75x | 0.65x | 0.46x | 0.58x |
| Revenue Growth | - | - | - | -19.57% | 53.37% | -65.52% | -3.79% | 54.14% | 185.66% | 21.31% |
ESPR SEC Filings & Documents
Esperion Therapeutics, Inc. (ESPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
ESPR Frequently Asked Questions
Esperion Therapeutics, Inc. (ESPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Esperion Therapeutics, Inc. (ESPR) reported $403.1M in revenue for fiscal year 2025.
Esperion Therapeutics, Inc. (ESPR) grew revenue by 21.3% over the past year. This is strong growth.
Esperion Therapeutics, Inc. (ESPR) reported a net loss of $22.7M for fiscal year 2025.
Dividend & Returns
Esperion Therapeutics, Inc. (ESPR) had negative free cash flow of $12.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More ESPR
Esperion Therapeutics, Inc. (ESPR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates